
World's richest 10% caused two-thirds of global warming: study
The world's wealthiest 10 percent of individuals are responsible for two-thirds of global warming since 1990, researchers said on Wednesday.
How the rich consume and invest has substantially increased the risk of deadly heatwaves and drought, they reported in the first study to quantify the impact of concentrated private wealth on extreme climate events.
"We link the carbon footprints of the wealthiest individuals directly to real-world climate impacts," lead author Sarah Schoengart, a scientist at ETH Zurich, told AFP.
"It's a shift from carbon accounting toward climate accountability."
Compared to the global average, for example, the richest one percent contributed 26 times more to once-a-century heatwaves, and 17 times more to droughts in the Amazon, according to the findings, published in Nature Climate Change.
Emissions from the wealthiest 10 percent in China and the United States - which together account for nearly half of global carbon pollution - each led to a two-to-threefold rise in heat extremes.
Burning fossil fuels and deforestation have heated Earth's average surface by 1.3 degrees Celsius, mostly during the last 30 years.
Schoengart and colleagues combined economic data and climate simulations to trace emissions from different global income groups and assess their impact on specific types of climate-enhance extreme weather.
The researchers also emphasised the role of emissions embedded in financial investment rather than just lifestyle and personal consumption.
"Climate action that doesn't address the outsized responsibilities of the wealthiest members of society risk missing one of the most powerful levers we have to reduce future harm," said senior author Carl-Friedrich Schleussner, head of the Integrated Climate Impacts Research Group at the International Institute for Applied Systems Analysis near Vienna.
Billionaires' tax
Owners of capital, he noted, could be held accountable for climate impacts through progressive taxes on wealth and carbon-intensive investments.
Earlier research has shown that taxing asset-related emissions is more equitable than broad carbon taxes, which tend to burden those on lower incomes.
Recent initiatives to increase taxes on the super-rich and multinationals have mostly stalled, especially since Donald Trump regained the White House.
Last year, Brazil - as host of the G20 - pushed for a two-percent tax on the net worth of individuals with more than $1 billion in assets.
Although G20 leaders agreed to "engage cooperatively to ensure that ultra-high-net-worth individuals are effectively taxed," there has been no follow-up to date.
In 2021, nearly 140 countries agreed on work toward a global corporate tax for multinational companies, with nearly half endorsing a minimum rate of 15 percent, but those talks have stalled as well.
Almost a third of the world's billionaires are from the United States - more than China, India and Germany combined, according to Forbes magazine.
According to anti-poverty NGO Oxfam, the richest 1 percent have accumulated $42 trillion in new wealth over the past decade.
It says the richest one percent have more wealth than the lowest 95 percent combined.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Geek Tyrant
22 minutes ago
- Geek Tyrant
Laika HIres SUSPIRIA Writer to Script Travis Knight's Surreal Stop-Motion Adaptation of PIRANESI — GeekTyrant
Laika's adaptation of Susanna Clarke's mind-bending fantasy novel Piranesi just took a major step forward with the hiring of acclaimed screenwriter Dave Kajganich to handle the script. Kajganich, known for his work on Suspiria , Bones and All , and AMC's The Terror , is currently collaborating with some of the most respected directors in the industry, including Barry Jenkins, Ridley Scott, and Edward Berger. Now, he'll bring his talents and skills to Laika's ambitious stop-motion take on Clarke's beloved novel. 'Piranesi changed my soul and is one of the books in all the world, of any era, I most cherish,' Kajganich said in a statement. 'Having Travis' and Susanna's trust in adapting it is something I take as an honor of the highest order. They are two of the loveliest, smartest, and most humane people you can imagine, so all of this is an actual dream coming true for me.' First announced in June 2024, Piranesi will be directed by Laika President & CEO Travis Knight, who previously helmed the Oscar-nominated Kubo and the Two Strings and the upcoming Wildwood . The project marks a return to the studio's roots in stop-motion storytelling, even as they continue branching out into live-action. The story for Piranesi is set in a dreamlike alternative reality, and it follows Piranesi, 'whose house is no ordinary building: its rooms are infinite, its corridors endless, its walls are lined with thousands upon thousands of statues, each one different from all the others. 'Within the labyrinth of halls, an ocean is imprisoned; waves thunder up staircases, rooms are flooded in an instant. But Piranesi is not afraid; he understands the tides as he understands the pattern of the labyrinth itself. He lives to explore the house.' There is one other person in the house, 'a man called The Other, who visits Piranesi twice a week and asks for help with research into A Great and Secret Knowledge. 'But as Piranesi explores, evidence emerges of another person, and a terrible truth begins to unravel, revealing a world beyond the one Piranesi has always known.' Since its release, Clarke's novel has become a literary phenomenon, selling over four million copies and winning the 2021 Women's Prize for Fiction. Its meditative tone, philosophical depth, and strange beauty seem tailor-made for Laika's visual storytelling. Knight previously shared in a statement: ' Piranesi is a treasure, and very dear to me. As a filmmaker, I can scarcely imagine a more joyful experience than wandering through the worlds Susanna dreamed into being. 'She's one of my all-time favorite authors, and with Piranesi , Susanna has created a beautiful, devastating and ultimately life-affirming work of art. I'm humbled that she chose LAIKA as her home.' Kajganich is also working on Brad Pitt's The Riders , he's also scripting Be My Baby , a Ronnie Spector biopic for A24, with Zendaya set to star and Barry Jenkins directing. While Laika continues to push further into live-action—with projects like Atmosphere from Anna Boden and Ryan Fleck, and Crumble from Brian Duffield and producers Phil Lord and Chris Miller, the studio hasn't lost sight of what made them a fan favorite in the first place: bold, stylized stop-motion animation that tell stories with emotional weight. Source: Deadline


Medscape
42 minutes ago
- Medscape
Taletrectinib Approved for NSCLC
The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to


Geek Tyrant
3 hours ago
- Geek Tyrant
Mia Goth Teases Guillermo del Toro's FRANKENSTEIN: 'People Are Going to Love How Epic it Is" — GeekTyrant
Guillermo del Toro's long-gestating Frankenstein is finally happening, and if you've been waiting for a version that honors the emotional weight and gothic grandeur of Mary Shelley's original novel, Mia Goth says you're in for something special. Goth, who plays Elizabeth Lavenza in the film, shared some insight during a red carpet chat with Entertainment Tonight at Netflix's TUDUM 2025 event. Her comments tease a film that is dark and dramatic, but also deeply human and visually massive. 'I think people are going to love how epic it is, and the scale of it, it's such a feast. But I think they will also be incredibly moved by it and maybe surprised by how much heart went into this. It's a lifelong project for Guillermo.' Del Toro's passion for Frankenstein is strong. Back in 2007, he said that he 'would kill to make' a faithful 'Miltonian tragedy' version of Shelley's novel. He's been dreaming of it for years, and now, thanks to Netflix, it's finally coming. The cast features Jacob Elordi takes on the iconic role of the monster, a transformation that left Goth floored: she says she was 'totally amazed' and 'just in awe.' Elordi is stepping into the shoes of one of horror's most misunderstood figures, and it sounds like he's doing so with style. Meanwhile, Oscar Isaac plays Victor Frankenstein, and Christoph Waltz appears in an as-yet-unnamed but reportedly key role. While Frankenstein has been adapted countless times over the last century, from Karloff's legendary performance to more stylized or sci-fi-heavy interpretations, this version promises a return to the emotional and philosophical core of Shelley's 1818 novel. Goth's comments on the film's emphasis on heart, is what separates Del Toro's monster tales from the rest… his creatures are rarely just creatures. They're metaphors, they're misunderstood, and they're always more than they appear. Frankenstein is set to premiere on Netflix in November 2025, and I'm incredibly excited about seeing Del Toro's vision for this story.